Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Inclusion criteria

• ✓. Participants must have histologically or cytologically confirmed advanced solid tumors (any solid tumor type) with:
• ✓. Expansion Cohort A (n=6): Germline mutation\* (with or without accompanying somatic mutation) in one or more of the following genes: BRCA1, BRCA2, PALB2, ATM, and/or CHEK2;
• ✓. Expansion Cohort B (n=6): Germline and/or somatic mutation\* in one or more of the following genes: BRCA1, BRCA2, PALB2, ATM, and/or CHEK2.
• ✓. Has measurable disease per RECIST 1.1 as assessed by the investigator. Lesions situated in previously irradiated areas are considered measurable if progression has been demonstrated in such lesions.
• ✓. Participants may have received any lines of prior therapy and is refractory or intolerant to therapy approved for their condition or unwilling to receive currently approved therapy.
• ✓. Prior PARP inhibitors are allowed, provided the following two criteria are met:
• ✓. Participant has NOT required toxicity related dose reductions or dose delays during prior PARP inhibitor treatment; and
• ✓. Participant has NOT experienced any allergic reaction to PARP inhibitors.

Exclusion criteria